$NBIX
NEUROCRINE BIOSCIENCES INC

2016 Q2 Form 10-Q Financial Statement

#000119312516580036 Filed on May 05, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $0.00 $15.00M $19.77M
YoY Change -24.12%
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $14.97M $12.00M $5.500M
YoY Change 126.74% 118.18% 30.95%
% of Gross Profit
Research & Development $26.86M $23.90M $16.58M
YoY Change 43.51% 44.21% 93.36%
% of Gross Profit
Depreciation & Amortization $300.0K $300.0K $200.0K
YoY Change 0.0% 50.0% 0.0%
% of Gross Profit
Operating Expenses $41.83M $35.86M $22.06M
YoY Change 65.18% 62.57% 73.34%
Operating Profit -$41.83M -$20.86M -$2.288M
YoY Change 65.18% 811.58% -82.02%
Interest Expense $0.00 $700.0K $300.0K
YoY Change -100.0% 133.33% 200.0%
% of Operating Profit
Other Income/Expense, Net $1.548M $1.593M $1.096M
YoY Change 15.96% 45.35% 24.12%
Pretax Income -$40.30M -$19.30M -$1.200M
YoY Change 67.92% 1508.33% -89.83%
Income Tax
% Of Pretax Income
Net Earnings -$40.28M -$19.26M -$1.192M
YoY Change 67.92% 1516.11% -89.93%
Net Earnings / Revenue -128.43% -6.03%
Basic Earnings Per Share
Diluted Earnings Per Share -$464.8K -$223.1K -$14.94K
COMMON SHARES
Basic Shares Outstanding 86.66M shares 86.45M shares 77.16M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $387.4M $381.5M $370.0M
YoY Change 0.7% 3.11% 68.26%
Cash & Equivalents $86.25M $115.3M $170.3M
Short-Term Investments $301.2M $266.2M $199.7M
Other Short-Term Assets $4.568M $4.377M $4.916M
YoY Change -2.73% -10.96%
Inventory
Prepaid Expenses
Receivables $15.10M $30.00M
Other Receivables $0.00 $0.00
Total Short-Term Assets $392.0M $401.0M $405.0M
YoY Change 0.65% -0.98% 82.63%
LONG-TERM ASSETS
Property, Plant & Equipment $5.811M $3.897M $2.543M
YoY Change 107.39% 53.24% 41.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $27.20M $49.50M $115.5M
YoY Change -76.18% -57.14% 125.15%
Other Assets $4.900M $5.000M $4.800M
YoY Change 2.08% 4.17% 9.09%
Total Long-Term Assets $37.87M $58.35M $122.8M
YoY Change -68.9% -52.5% 113.38%
TOTAL ASSETS
Total Short-Term Assets $392.0M $401.0M $405.0M
Total Long-Term Assets $37.87M $58.35M $122.8M
Total Assets $429.8M $459.3M $527.8M
YoY Change -15.92% -12.97% 88.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.762M $2.122M $1.270M
YoY Change 70.24% 67.09% 55.26%
Accrued Expenses $21.02M $17.13M $9.938M
YoY Change 69.6% 72.33% 62.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.90M $23.28M $15.19M
YoY Change 53.24% 53.26% 43.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $113.0K $221.0K $260.0K
YoY Change -53.88% -15.0% 0.0%
Total Long-Term Liabilities $113.0K $221.0K $260.0K
YoY Change -53.88% -15.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.90M $23.28M $15.19M
Total Long-Term Liabilities $113.0K $221.0K $260.0K
Total Liabilities $48.80M $46.37M $43.05M
YoY Change 10.25% 7.72% 33.53%
SHAREHOLDERS EQUITY
Retained Earnings -$974.8M -$934.5M -$827.5M
YoY Change 14.48% 12.93% 6.42%
Common Stock $1.356B $1.348B $85.00K
YoY Change 1576475.58% 1585364.71% 11.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $381.0M $413.0M $484.7M
YoY Change
Total Liabilities & Shareholders Equity $429.8M $459.3M $527.8M
YoY Change -15.92% -12.97% 88.97%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$40.28M -$19.26M -$1.192M
YoY Change 67.92% 1516.11% -89.93%
Depreciation, Depletion And Amortization $300.0K $300.0K $200.0K
YoY Change 0.0% 50.0% 0.0%
Cash From Operating Activities -$14.30M -$29.20M -$18.20M
YoY Change -202.14% 60.44% 85.71%
INVESTING ACTIVITIES
Capital Expenditures -$2.300M $741.0K $280.0K
YoY Change 360.0% 164.64% 9.8%
Acquisitions
YoY Change
Other Investing Activities -$13.40M $71.00M -$115.8M
YoY Change -74.91% -161.31% 76.79%
Cash From Investing Activities -$15.70M $70.30M -$116.1M
YoY Change -70.87% -160.55% 76.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $62.00K $270.7M
YoY Change -99.98% 103.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 900.0K 100.0K 273.5M
YoY Change -50.0% -99.96% 100.81%
NET CHANGE
Cash From Operating Activities -14.30M -29.20M -18.20M
Cash From Investing Activities -15.70M 70.30M -116.1M
Cash From Financing Activities 900.0K 100.0K 273.5M
Net Change In Cash -29.10M 41.20M 139.2M
YoY Change -23.62% -70.4% 129.32%
FREE CASH FLOW
Cash From Operating Activities -$14.30M -$29.20M -$18.20M
Capital Expenditures -$2.300M $741.0K $280.0K
Free Cash Flow -$12.00M -$29.94M -$18.48M
YoY Change -182.76% 62.02% 83.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86656029 shares
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
170262000
CY2015Q1 nbix Cease Use Liability
CeaseUseLiability
2565000
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86573076 shares
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86573076 shares
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
23276000
CY2016Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17126000
CY2016Q1 us-gaap Liabilities
Liabilities
46373000
CY2016Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
345000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
87000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1347558000
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
221000
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-188000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-934498000
CY2016Q1 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
13500000
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1817000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
412959000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
459332000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2122000
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3897000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
315683000
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4991000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
400984000
CY2016Q1 us-gaap Other Assets Current
OtherAssetsCurrent
4377000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
177986000
CY2016Q1 us-gaap Investments
Investments
315700000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
293000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115301000
CY2016Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
15083000
CY2016Q1 us-gaap Assets
Assets
459332000
CY2016Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
49460000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
5000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
5074000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
298000
CY2016Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
266223000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
172912000
CY2016Q1 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2016Q1 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
4600000
CY2016Q1 nbix Cease Use Liability
CeaseUseLiability
1043000
CY2016Q1 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
10019000
CY2016Q1 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
809000
CY2016Q1 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
234000
CY2016Q1 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3449000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31014000
CY2014Q4 nbix Cease Use Liability
CeaseUseLiability
2678000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86262594 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86262594 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25715000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19034000
CY2015Q4 us-gaap Liabilities
Liabilities
50331000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
269000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
86000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1340579000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
221000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-977000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-915234000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1711000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
424454000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
474785000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2561000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
387484000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4791000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3432000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
384074000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4883000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
364070000
CY2015Q4 us-gaap Investments
Investments
387500000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
959000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74195000
CY2015Q4 us-gaap Assets
Assets
474785000
CY2015Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
82488000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
22000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
5521000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
981000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
304996000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
358549000
CY2015Q4 nbix Cease Use Liability
CeaseUseLiability
1983000
CY2015Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
10898000
CY2015Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
1555000
CY2015Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
428000
CY2015Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3423000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270700000
CY2015Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
200000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
700000 shares
CY2015Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3900000 shares
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18183000
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
700000 shares
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80349000 shares
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1094000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
280000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1011000
CY2015Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
839000
CY2015Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
159221000
CY2015Q1 us-gaap Licenses Revenue
LicensesRevenue
19769000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2288000
CY2015Q1 us-gaap Revenues
Revenues
19769000
CY2015Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
CY2015Q1 us-gaap Investment Income Net
InvestmentIncomeNet
257000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1096000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
30552000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-1192000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
98000
CY2015Q1 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
800000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
273525000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
244000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
22057000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
273525000
CY2015Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-27000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5482000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10231000
CY2015Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-546000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
139248000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3600000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3600000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43398000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-116094000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2800000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16575000
CY2015Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
830000
CY2015Q1 nbix Cease Use Expense
CeaseUseExpense
0
CY2015Q1 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
113000
CY2015Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-113000
CY2015Q1 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
0
CY2015Q1 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
9000
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Trading Symbol
TradingSymbol
NBIX
CY2016Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
300000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
700000 shares
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3600000 shares
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000 shares
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-29211000
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
26000.0 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q1 us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p> </div>
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86497000 shares
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18475000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
741000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1397000
CY2016Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
856000
CY2016Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
55561000
CY2016Q1 us-gaap Licenses Revenue
LicensesRevenue
15000000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-20857000
CY2016Q1 us-gaap Revenues
Revenues
15000000
CY2016Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
737000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1593000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
14577000
CY2016Q1 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
1100000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-19264000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
789000
CY2016Q1 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
900000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
276000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
35857000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
62000
CY2016Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-64000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11954000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2016Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2347000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41106000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6900000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6918000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
126754000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
70255000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23903000
CY2016Q1 nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
CY2016Q1 nbix Subleased Agreement Area
SubleasedAgreementArea
30000 sqft
CY2016Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
853000
CY2016Q1 nbix Cease Use Expense
CeaseUseExpense
-584000
CY2016Q1 nbix Lease Expiration Year
LeaseExpirationYear
2019
CY2016Q1 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
110000
CY2016Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-110000
CY2016Q1 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-830000
CY2016Q1 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
3000

Files In Submission

Name View Source Status
0001193125-16-580036-index-headers.html Edgar Link pending
0001193125-16-580036-index.html Edgar Link pending
0001193125-16-580036.txt Edgar Link pending
0001193125-16-580036-xbrl.zip Edgar Link pending
d178294d10q.htm Edgar Link pending
d178294dex311.htm Edgar Link pending
d178294dex312.htm Edgar Link pending
d178294dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nbix-20160331.xml Edgar Link completed
nbix-20160331.xsd Edgar Link pending
nbix-20160331_cal.xml Edgar Link unprocessable
nbix-20160331_def.xml Edgar Link unprocessable
nbix-20160331_lab.xml Edgar Link unprocessable
nbix-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending